# Extracorporeal SPecific IgE Removal From the Plasma of Allergic Asthma Patients (ESPIRA-study)

> **NCT02096237** · NA · COMPLETED · sponsor: **Fresenius Medical Care Deutschland GmbH** · enrollment: 14 (actual)

## Conditions studied

- Allergic Asthma

## Interventions

- **DEVICE:** IgE adsorber

## Key facts

- **NCT ID:** NCT02096237
- **Lead sponsor:** Fresenius Medical Care Deutschland GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12
- **Primary completion:** 2014-07
- **Final completion:** 2014-11
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2015-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02096237

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02096237, "Extracorporeal SPecific IgE Removal From the Plasma of Allergic Asthma Patients (ESPIRA-study)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02096237. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*